Literature DB >> 22965242

The biological activity of auranofin: implications for novel treatment of diseases.

J M Madeira1, D L Gibson, W F Kean, A Klegeris.   

Abstract

More than 30 years ago, auranofin was developed for the treatment of rheumatoid arthritis as a substitution for the injectable gold compounds aurothiomalate and aurothioglucose. Both the ease of oral administration over intramuscular injections and more potent anti-inflammatory effects in vitro made auranofin seem like an excellent substitute for the traditional injectable gold compounds. Despite efficacy in the treatment of both rheumatoid arthritis and psoriasis, currently, auranofin is seldom used as a treatment for patients with rheumatoid arthritis as more novel anti-rheumatic medications have become available. Despite the decline in its clinical applications, research on auranofin has continued as it shows promise in the treatment of several different diseases. In recent years, advances in technology have allowed researchers to use molecular techniques to identify novel mechanisms of action of auranofin. Additionally, researchers are discovering potential new applications of auranofin. Dual inhibition of inflammatory pathways and thiol redox enzymes by auranofin makes it a new candidate for cancer therapy and treating microbial infections. This review will summarize recently obtained data on the mechanisms of action of auranofin, and potential new applications of auranofin in the treatment of various diseases, including several types of leukaemia, carcinomas, and parasitic, bacterial, and viral infections.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965242     DOI: 10.1007/s10787-012-0149-1

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  75 in total

Review 1.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

Authors:  A W Griffioen; G Molema
Journal:  Pharmacol Rev       Date:  2000-06       Impact factor: 25.468

2.  Auranofin inhibits interleukin-1beta-induced transcript of cyclooxygenase-2 on cultured human synoviocytes.

Authors:  R Yamada; H Sano; T Hla; A Hashiramoto; W Fukui; S Miyazaki; M Kohno; Y Tsubouchi; Y Kusaka; M Kondo
Journal:  Eur J Pharmacol       Date:  1999-11-26       Impact factor: 4.432

3.  Heat shock-induced matrix metalloproteinase (MMP)-1 and MMP-3 are mediated through ERK and JNK activation and via an autocrine interleukin-6 loop.

Authors:  Chi-Hyun Park; Min Jung Lee; Jungmi Ahn; Sangmin Kim; Hyeon Ho Kim; Kyu Han Kim; Hee Chul Eun; Jin Ho Chung
Journal:  J Invest Dermatol       Date:  2004-12       Impact factor: 8.551

4.  Gold-induced reactive oxygen species (ROS) do not mediate suppression of monocytic mitochondrial or secretory function.

Authors:  Yo Omata; Jill B Lewis; Petra E Lockwood; Wan Y Tseng; Regina L Messer; Serge Bouillaguet; John C Wataha
Journal:  Toxicol In Vitro       Date:  2005-12-27       Impact factor: 3.500

5.  Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages.

Authors:  M Yamashita; H Niki; M Yamada; M Watanabe-Kobayashi; S Mue; K Ohuchi
Journal:  Eur J Pharmacol       Date:  1997-05-01       Impact factor: 4.432

6.  Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite.

Authors:  E R Frears; Z Zhang; D R Blake; J P O'Connell; P G Winyard
Journal:  FEBS Lett       Date:  1996-02-26       Impact factor: 4.124

Review 7.  Clinical pharmacology of gold.

Authors:  W F Kean; I R L Kean
Journal:  Inflammopharmacology       Date:  2008-06       Impact factor: 4.473

8.  Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a single thioredoxin glutathione reductase and dependent on selenium and glutathione.

Authors:  Mariana Bonilla; Ana Denicola; Sergey V Novoselov; Anton A Turanov; Anna Protasio; Darwin Izmendi; Vadim N Gladyshev; Gustavo Salinas
Journal:  J Biol Chem       Date:  2008-04-11       Impact factor: 5.157

9.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

10.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Authors:  Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins
Journal:  Neuro Oncol       Date:  2009-05-12       Impact factor: 12.300

View more
  51 in total

1.  X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action.

Authors:  Derek Parsonage; Fang Sheng; Ken Hirata; Anjan Debnath; James H McKerrow; Sharon L Reed; Ruben Abagyan; Leslie B Poole; Larissa M Podust
Journal:  J Struct Biol       Date:  2016-02-12       Impact factor: 2.867

Review 2.  The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells.

Authors:  Lianqin Li; Ai-Qun Yu
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-21       Impact factor: 4.553

3.  Selective inhibitory effects of 50-nm gold nanoparticles on mouse macrophage and spleen cells.

Authors:  Micah Kingston; Jean C Pfau; John Gilmer; Richard Brey
Journal:  J Immunotoxicol       Date:  2015-04-15       Impact factor: 3.000

4.  Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.

Authors:  Michael B Harbut; Catherine Vilchèze; Xiaozhou Luo; Mary E Hensler; Hui Guo; Baiyuan Yang; Arnab K Chatterjee; Victor Nizet; William R Jacobs; Peter G Schultz; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

5.  Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells.

Authors:  Xin Chen; Xianping Shi; Xuejun Wang; Jinbao Liu
Journal:  Cancer Cell Microenviron       Date:  2014-11-01

Review 6.  Nanotechnology in radiation oncology.

Authors:  Andrew Z Wang; Joel E Tepper
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

7.  Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi.

Authors:  Nathan P Wiederhold; Thomas F Patterson; Anand Srinivasan; Ashok K Chaturvedi; Annette W Fothergill; Floyd L Wormley; Anand K Ramasubramanian; José L Lopez-Ribot
Journal:  Virulence       Date:  2016-06-07       Impact factor: 5.882

8.  Repurposing auranofin for treatment of Experimental Cerebral Toxoplasmosis.

Authors:  Iman Fathy Abou-El-Naga; Nermine Mogahed Fawzy Hussein Mogahed
Journal:  Acta Parasitol       Date:  2021-02-08       Impact factor: 1.440

9.  KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.

Authors:  Bingbing Dai; Suk-Young Yoo; Geoffrey Bartholomeusz; Ryan A Graham; Mourad Majidi; Shaoyu Yan; Jieru Meng; Lin Ji; Kevin Coombes; John D Minna; Bingliang Fang; Jack A Roth
Journal:  Cancer Res       Date:  2013-07-03       Impact factor: 12.701

10.  Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains.

Authors:  Yozane Hokai; Boruch Jurkowicz; Jacob Fernández-Gallardo; Nuruddinkodja Zakirkhodjaev; Mercedes Sanaú; Theodore R Muth; María Contel
Journal:  J Inorg Biochem       Date:  2014-05-28       Impact factor: 4.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.